In Brief: Ephedrine abuse data collection
This article was originally published in The Tan Sheet
Executive Summary
Ephedrine abuse data collection: FDA requests information on the abuse potential, actual abuse, medical usefulness and trafficking of ephedrine and two Rx drug substances dihydroetorphine and remifentanil (Glaxo Wellcome's Ultiva), in a March 18 Federal Register notice. The agency will consider the comments when preparing a statement for the World Health Organization regarding the drugs. WHO is meeting June 23-26 to review the substances. Written comments are due to the agency by April 17...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning